ENXTPA:ABVXBiotechs
A Look At Abivax (ENXTPA:ABVX) Valuation After Positive Phase 3 Obefazimod Ulcerative Colitis Data
ABIVAX Société Anonyme (ENXTPA:ABVX) is drawing attention after reporting that its lead drug candidate obefazimod showed efficacy with a clean safety profile in a Phase 3 ulcerative colitis trial, alongside plans for further pivotal studies.
See our latest analysis for ABIVAX Société Anonyme.
The recent Phase 3 ulcerative colitis result and takeover speculation arrive after a mixed stretch for the share price, with a 1 day share price return of 2.99%, a 30 day share price return decline of...